Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients.
Lupo-Stanghellini MT, Di Cosimo S, Costantini M, Monti S, Mantegazza R, Mantovani A, Salvarani C, Zinzani PL, Inglese M, Ciceri F, Apolone G, Ciliberto G, Baldanti F, Morrone A, Sinno V, Locatelli F, Notari S, Turola E, Giannarelli D, Silvestris N. Lupo-Stanghellini MT, et al. Among authors: sinno v. Front Oncol. 2022 Mar 17;12:855723. doi: 10.3389/fonc.2022.855723. eCollection 2022. Front Oncol. 2022. PMID: 35371993 Free PMC article.
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Corradini P, et al. Among authors: sinno v. Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404. Clin Infect Dis. 2023. PMID: 35607769 Free PMC article.
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Among authors: sinno v. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Lorusso D, Maltese G, Sabatucci I, Cresta S, Matteo C, Ceruti T, D'Incalci M, Zucchetti M, Raspagliesi F, Sonetto C, Sinno V, Ronzulli D, Giolitto S, de Braud F. Lorusso D, et al. Among authors: sinno v. Target Oncol. 2021 Jan;16(1):59-68. doi: 10.1007/s11523-020-00780-4. Epub 2020 Dec 28. Target Oncol. 2021. PMID: 33369704 Free PMC article. Clinical Trial.